subscribeSubscribe
Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer

Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer
BUSINESSWIRE
09 Dec 2023
Share Share
Seagen says Tukysa combo hits main goal in Phase III breast cancer study

Seagen says Tukysa combo hits main goal in Phase III breast cancer study
BUSINESSWIRE
17 Aug 2023
Share Share
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial

Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
BUSINESSWIRE
07 Dec 2022
Share Share
ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%

ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%
BUSINESSWIRE
07 Dec 2022
Share Share
Genentech`s Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.

Genentech`s Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.
FDA
02 Feb 2022
Share Share
ENHERTU Additional Analyses Reinforce Ground-breaking Efficacy in Breast Cancer

ENHERTU Additional Analyses Reinforce Ground-breaking Efficacy in Breast Cancer
BUSINESSWIRE
09 Dec 2021
Share Share
Daiichi Sankyo to Present New Breast Cancer Data at 2021 SABCS

Daiichi Sankyo to Present New Breast Cancer Data at 2021 SABCS
BUSINESSWIRE
01 Dec 2021
Share Share
Hope Soars at ESMO 2021 for Breast Cancer Treatments

Hope Soars at ESMO 2021 for Breast Cancer Treatments
Alex Keown BIOSPACE
20 Sep 2021
Share Share
AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data

AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data
BUSINESSWIRE
13 May 2020
Share Share
NICE backs Roche`s Kadcyla for HER2-positive early breast cancer

NICE backs Roche`s Kadcyla for HER2-positive early breast cancer
Selina McKee PHARMATIMES
11 May 2020
Share Share